| Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis D Baeten, J Sieper, J Braun, X Baraliakos, M Dougados, P Emery, ... New England journal of medicine 373 (26), 2534-2548, 2015 | 1165 | 2015 |
| 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of … MM Ward, A Deodhar, LS Gensler, M Dubreuil, D Yu, MA Khan, N Haroon, ... Arthritis & rheumatology 71 (10), 1599-1613, 2019 | 947 | 2019 |
| 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis JA Singh, G Guyatt, A Ogdie, DD Gladman, C Deal, A Deodhar, ... Journal of Psoriasis and Psoriatic arthritis 4 (1), 31-58, 2019 | 824 | 2019 |
| American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing … MM Ward, A Deodhar, EA Akl, A Lui, J Ermann, LS Gensler, JA Smith, ... Arthritis care & research 68 (2), 151-166, 2016 | 663 | 2016 |
| Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force JS Smolen, J Braun, M Dougados, P Emery, O FitzGerald, P Helliwell, ... Annals of the rheumatic diseases 73 (1), 6-16, 2014 | 636 | 2014 |
| Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) PJ Mease, R Fleischmann, AA Deodhar, J Wollenhaupt, M Khraishi, ... Annals of the rheumatic diseases 73 (1), 48-55, 2014 | 618 | 2014 |
| Research and development spending to bring a single cancer drug to market and revenues after approval V Prasad, S Mailankody JAMA internal medicine 177 (11), 1569-1575, 2017 | 551 | 2017 |
| Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial CO Bingham III, RJ Looney, A Deodhar, N Halsey, M Greenwald, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2010 | 512 | 2010 |
| Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis PJ Mease, MC Genovese, MW Greenwald, CT Ritchlin, AD Beaulieu, ... New England Journal of Medicine 370 (24), 2295-2306, 2014 | 481 | 2014 |
| Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised … P Nash, B Kirkham, M Okada, P Rahman, B Combe, GR Burmester, ... The Lancet 389 (10086), 2317-2327, 2017 | 472 | 2017 |
| Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological … D van der Heijde, JCC Wei, M Dougados, P Mease, A Deodhar, ... The Lancet 392 (10163), 2441-2451, 2018 | 404 | 2018 |
| Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study D Van Der Heijde, A Deodhar, JC Wei, E Drescher, D Fleishaker, ... Annals of the rheumatic diseases 76 (8), 1340-1347, 2017 | 402 | 2017 |
| Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised … A Deodhar, PS Helliwell, WH Boehncke, AP Kollmeier, EC Hsia, ... The Lancet 395 (10230), 1115-1125, 2020 | 378 | 2020 |
| Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial D van der Heijde, IH Song, AL Pangan, A Deodhar, F Van den Bosch, ... The Lancet 394 (10214), 2108-2117, 2019 | 370 | 2019 |
| Bone mass measurement and bone metabolism in rheumatoid arthritis: a review AA Deodhar, AD Woolf Rheumatology 35 (4), 309-322, 1996 | 352 | 1996 |
| Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis A Deodhar, LS Gensler, J Sieper, M Clark, C Calderon, Y Wang, Y Zhou, ... Arthritis & Rheumatology 71 (2), 258-270, 2019 | 333 | 2019 |
| The classification and diagnostic criteria of ankylosing spondylitis SP Raychaudhuri, A Deodhar Journal of autoimmunity 48, 128-133, 2014 | 326 | 2014 |
| Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study A Moltó, A Etcheto, D Van Der Heijde, R Landewé, F Van Den Bosch, ... Annals of the rheumatic diseases 75 (6), 1016-1023, 2016 | 307 | 2016 |
| Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study J Braun, X Baraliakos, A Deodhar, D Baeten, J Sieper, P Emery, A Readie, ... Annals of the rheumatic diseases 76 (6), 1070-1077, 2017 | 302 | 2017 |
| MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group WP Maksymowych, RGW Lambert, M Østergaard, SJ Pedersen, ... Annals of the rheumatic diseases 78 (11), 1550-1558, 2019 | 285 | 2019 |
